Treatment Strategy of Lung Adenocarcinoma with Concomitant EGFR Mutation and ALK Rearrangement

The incidence of synchronous mutations of Epidermal growth factor receptor (EGFR) and anaplastic large-cell lymphoma kinase (ALK) rearrangements in non-small cell lung cancer (NSCLC) was low. Now clinical experience is still insufficient. Simultaneously the treatment of brain metastasis hemorrhage in the acute phase with lung cancer is still controversial. We described the clinical treatment strategy of a patient with synchronous mutations of EGFR and ALK.We found that the tumor was well controlled. Progression-free survival (PFS)1 was 4 months, PFS2 was 3 months, PFS3 was 5 months, PFS4 was 5 months, and PFS5 was 9 months. At present, the patient still maintains partial response (PR) status. READ ARTICLE

Research Square DOI:10.21203/rs.3.rs-718876/v1

Authors: Li Li , Wei Liu , Chunhua Xu, Jue Zou

Case StudyKirk SmithJuly 29, 2021lung adenocarcinoma, EGFR/ALK co-altered, Case report, brain metastases

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report

Background The prevalence of EGFR/ALK co-alterations in patients with NSCLC was low. The several previous studies focused on the simultaneous occurrence of EGFR mutations and ALK rearrangements in a unifocal lung cancer. However, the incidence of multifocal pulmonary adenocarcinomas was increasingly encountered in clinical practice, due to the increased availability and improvement of the thoracic imaging. The clinical relevance of EGFR/ALK co-alterations in multifocal adenocarcinomas required detailed investigation as well. ConclusionsThe status of the oncogenic mutations in lymph node metastasis may provide some effective hints for metastasis lesion in other organ or tissue. Therefore, it is recommended to fully evaluate the driver genes in lymph node metastasis after radical resection. READ ARTICLE

Diagnostic Pathology DOI:10.1186/s13000-020-00969-1

Authors: Fan, J., Wu, J., Huang, B. et al.

Case StudyKirk SmithMay 6, 2020Multifocal lung adenocarcinoma, EGFR/ALK co-altered